仟源医药：9月15日召开董事会会议

Group 1 - The core point of the article is that Qianyuan Pharmaceutical announced a board meeting to discuss the proposal for engaging in financing leasing business [1] - For the year 2024, the revenue composition of Qianyuan Pharmaceutical is as follows: 96.68% from pharmaceutical manufacturing, 1.93% from DNA gene preservation and prenatal environment testing services, 0.79% from health food, 0.51% from other businesses, and 0.1% from commercial activities [1] - As of the report date, Qianyuan Pharmaceutical has a market capitalization of 2.7 billion yuan [1] Group 2 - A significant breakthrough has been recognized for a new drug in China, which has been acknowledged by both Chinese and American officials for its breakthrough efficacy, generating excitement at the World Lung Cancer Conference [1]